Becker Muscular Dystrophy research hub
4 indexed studies · 1 currently recruiting
- active not recruitingPHASE2
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
This study is testing a new medicine called sevasemten (also known as EDG-5506) for adults with Becker muscular dystrophy. It wants to see if the medicine is safe and if it helps people. Early parts of the study are now full, but one large part, GRAND CANYON, has also finished taking new participants.
United States · Australia · Belgium - enrolling by invitationPHASE2
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
This study looks at the long-term effects of a medication called sevasemten for people with Becker muscular dystrophy. It wants to see if the medicine is safe and if it helps with the condition over a longer time. Only people who have been in earlier studies with this medicine can join.
United States · Belgium · Denmark - active not recruiting
Defining Endpoints in Becker Muscular Dystrophy
This study looks at Becker muscular dystrophy over two years. It aims to understand how the condition changes over time in 50 people. This will help doctors plan better treatments in the future. It doesn't involve new medicines.
United States · New Zealand · United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effect of EDG-5506 on Biomarker Response to Exercise in Adults with Becker Muscular Dystrophy, McArdle Disease, or Limb-Girdle Muscular Dystrophy
This study is testing a new medicine, EDG-5506, for people with Becker muscular dystrophy, McArdle disease, or limb-girdle muscular dystrophy. We want to see if it helps reduce muscle damage and if it's safe. It's compared to a dummy medicine.
Denmark